title: Outcomes of extremely low risk prostate cancer following radical prostatectomy.
abstract: The optimal management of men with very favorable clinicopathological factors who develop biochemical recurrence (BCR) after radical prostatectomy (RP) has not been previously reported. Both local and systemic recurrences are unlikely in this cohort. This study examines their management and outcomes. Between October 2000 to March 2010, 1627 men underwent open RP by a single surgeon. In all, 448 (27.5%) met the following criteria for extremely low risk disease: preoperative PSA level <10 ng ml(-1), clinical stage T1c/T2a, Gleason score 6, estimated cancer volume in the surgical specimen 5% and no evidence for positive surgical margin. Undetectable PSA was defined as 0.04 ng ml(-1). BCR was defined as PSA 0.2 ng ml(-1) or initiation of salvage radiation therapy (SRT) for progressively rising PSA. At 54 months mean follow-up (range 3-114 months), 9 (2%) of the 448 men developed BCR. Mean time to BCR was 63 months (range 12-93) and mean PSA doubling time was 15 months (range 6-27). Six underwent SRT, two elected surveillance and one was lost to follow-up. All men undergoing SRT exhibited more than 75% reduction in pre-SRT PSA, indicating the presence of local disease recurrence. All men undergoing SRT maintained PSA levels <0.1 at last follow-up. The BCR of 2% confirmed that we selected a cohort with extremely low risk for BCR after RP. We demonstrated that men fulfilling our criteria who develop BCR all harbor local disease based on favorable response to SRT. These men should be managed with SRT if recurrence is felt to be biologically significant.
authors.affiliation: Department of Urology, New York University School of Medicine, New York, NY 10016, USA.
authors.forename: E W
authors.initials: EW
authors.lastname: Lee
authors.forename: J
authors.initials: J
authors.lastname: Laze
authors.forename: H
authors.initials: H
authors.lastname: Lepor
mesh_terms: D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000517:prevention & control* / Q000532:radiotherapy; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000517:prevention & control* / Q000532:radiotherapy / Q000601:surgery; D012306:Risk; D016896:Treatment Outcome
chemical_list: D017430:Prostate-Specific Antigen